Nordin Nor Asyikin, Sadikan Muhammad Zulfiqah, Lambuk Lidawani, Hashim Sabarisah, Airuddin Syahira, Mohd Nasir Nur-Azida, Mohamud Rohimah, Ibrahim Jamal, Kadir Ramlah
Department of Immunology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
Department of Pharmacology, Faculty of Medicine, Manipal University College Malaysia (MUCM), 75150 Bukit Baru, Melaka, Malaysia.
J Pharm Pharmacol. 2025 Apr 3;77(4):475-491. doi: 10.1093/jpp/rgae129.
Glaucoma is a leading cause of permanent blindness. Despite therapeutic advancements, glaucoma management remains challenging due to limitations of conventional drug delivery, primarily topical eye drops, resulting in suboptimal outcomes and a global surge in cases. To address these issues, liposomal drug delivery has emerged as a promising approach.
This review explores the potential of liposomal-based medications, with a particular focus on topical administration as a superior alternative to enhance therapeutic efficacy and improve patient compliance compared to existing treatments. This writing delves into the therapeutic prospects of liposomal formulations across different administration routes, as evidenced by ongoing clinical trials. Additionally, critical aspects of liposomal production and market strategies are discussed herein.
By overcoming ocular barriers and optimizing drug delivery, liposomal topical administration holds the key to significantly improving glaucoma treatment outcomes.
青光眼是导致永久性失明的主要原因。尽管治疗取得了进展，但由于传统给药方式（主要是局部滴眼液）的局限性，青光眼的管理仍然具有挑战性，导致治疗效果不理想，且全球病例数激增。为了解决这些问题，脂质体药物递送已成为一种有前景的方法。
本综述探讨了基于脂质体的药物的潜力，特别关注局部给药，作为一种优于现有治疗方法的替代方案，以提高治疗效果并改善患者依从性。本文深入研究了脂质体剂型在不同给药途径中的治疗前景，正在进行的临床试验证明了这一点。此外，本文还讨论了脂质体制备和市场策略的关键方面。
通过克服眼部屏障和优化药物递送，脂质体局部给药是显著改善青光眼治疗效果的关键。
